ERC Starting Grant · 2018
Studying Cancer Individuality by Personal and Predictive Drug Screening and Differential OMICs
The cellular and molecular systems that determine drug responses in cancer are complex, highly individual, and incompletely understood. As a result, many cancer patients receive ineffective or even harmful therapies, which endangers lives, burdens healthcare systems, and prevents new therapies from reaching clinical approval. To address this problem, we are developing a platform that measures hundreds of ex vivo drug responses from small patient biopsies by immunofluorescence, automated confocal microscopy, single-cell image analysis, and machine learning. We preserve cellular memory and maximize physiological relevance by not culturing or sorting cells prior to drug exposure. Sub-cellular,…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at Swiss Federal Institute of Technology Zurich (ETH Zurich)